ArticlePloS one2015
Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis.European radiology · 2021Pooled it
- Review
- Review
- Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center studyDiagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Clinical significance of contrast extravasation on computed tomography immediately after thermal ablation for hepatic tumors.BMC gastroenterology · 2025Article
- Molecular MRI of T-cell immune response to cryoablation in immunologically hotJHEP reports : innovation in hepatology · 2025Article
- Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.World journal of radiology · 2025Review
- [Guidelines for image-guided ablation of primary liver cancer (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Improved Thermal Sensitivity Using Virtual Monochromatic Imaging Derived from Photon Counting Detector CT Data Sets: Ex Vivo Results of CT-Guided Cryoablation in Porcine Liver.Cardiovascular and interventional radiology · 2023Article
- Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023Review
- Role of Percutaneous Ablation in the Management of Intrahepatic Cholangiocarcinoma.Medicina (Kaunas, Lithuania) · 2023Review
- Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases.Diagnostics (Basel, Switzerland) · 2023Review
- Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors.Cancers · 2023Article
- Interventional Radiology in the Treatment of Pancreatic Adenocarcinoma: Present and Future Perspectives.Life (Basel, Switzerland) · 2023Review
- Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.The Indian journal of radiology & imaging · 2022Review
- Editorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis.Hepatobiliary surgery and nutrition · 2022Article
- Metastatic disease to the liver: Locoregional therapy strategies and outcomes.World journal of clinical oncology · 2021Review
- A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis.Hepatobiliary surgery and nutrition · 2021Review
- Advanced Techniques in the Percutaneous Ablation of Liver Tumours.Diagnostics (Basel, Switzerland) · 2021Review
- The role of interventional radiology in the treatment of patients with pancreatic cancer.The British journal of radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidences have suggested that percutaneous cryoablation could be a valuable alternative ablation therapy for HCC but there has been no large cohort-based analysis on its long-term outcomes.
methodsA series of 866 patients with Child-Pugh class A-B cirrhosis and HCC within Milan criteria who underwent percutaneous cryoablation was long-term followed. The safety, efficacy, 5-year survival, and prognostic factors of percutaneous cryoablation in the treatment of HCC were analyzed.
resultsA total of 1197 HCC lesions were ablated with 1401 cryoablation sessions. Complete response (CR) was achieved in 1163 (97.2%) lesions and 832 (96.1%) patients with 34 (2.8%) major complications, but no treatment-related mortality. After a median of 30.9 months follow-up, 502 (60.3%) patients who achieved CR developed different types of recurrence. The cumulative local tumor recurrence rate was 24.2% at 5-years. Multiple tumor lesions, tumor size > 3 cm, and repeated ablation of same lesion were independent risk factors associated with local recurrence. The 5-year overall survival (OS) rates were 59.5%. Age < 36 years, HCC family history, baseline hepatitis B virus DNA >106 copies/ml, and three HCC lesions were independently and significantly negative predictors to the post-cryoablation OS.
conclusionsPercutaneous cryoablation is an effective therapy for patients with HCC within Milan criteria, with comparable efficacy, safety and long-term survival to the reported outcomes of radiofrequency ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.